These Case-Based Roundtable article and video series explore recent perspectives on treatment strategies around clinical case profiles.
Expanding Second-Line Therapy in B-cell Lymphoma with CAR T-Cell Therapy
April 27th 2024This roundtable series looks at the use of CAR T-cell therapy for patients with large B-cell lymphoma and how this is expanding treatment options for these patients in the second-line setting, as discussed by key opinion leaders and participants at virtual live events.
Therapeutic Choices for Patients With HR-Positive, HER2-Low Breast Cancer
March 15th 2024This Evolving Paradigm Roundtable reviews the later-line options for patients with hormone receptor–positive, HER2-low or -negative inoperable or metastatic breast cancer, as discussed by key opinion leaders and participants at virtual live events.
Treatment Options in Patients With R/R Multiple Myeloma in the Later-Line Setting
September 27th 2023This roundtable series evaluates therapies for patients with relapsed/refractory multiple myeloma after they have recieved multiple types of treatment, as discussed by key opinion leaders and participants at virtual live events.
Therapeutic Choices in dMMR Recurrent or Advanced Endometrial Cancer
August 10th 2023This roundtable series reviews options after progression on platinum-regimens for patients with mismatch repair–deficient recurrent or advanced endometrial cancer, as discussed by key opinion leaders and participants at virtual live events.
Treating Patients With Metastatic or Recurrent Cervical Cancer Post Chemotherapy
July 27th 2023This roundtable series discusses antibody-drug conjugates as therapy for patients with cervical cancer who had progressed on chemotherapy, as discussed by key opinion leaders and participants at virtual live events.
Options Post First-Line Progression in mCRPC With HRR Mutations
May 22nd 2023This roundtable series assesses treatment after first-line progression for patients with deleterious germline or somatic homologous recombination repair-mutated metastatic castration-resistant prostate cancer, as discussed by key opinion leaders and participants at virtual live events.
Patients With Advanced Hodgkin Lymphoma Treated Using Frontline Immunotherapy Plus Chemotherapy
March 29th 2023This roundtable series evaluates the use of combination therapies using immunotherapy and chemotherapy in patients with advanced Hodgkin lymphoma, as discussed by key opinion leaders and participants at virtual live events.
Therapeutic Options for Patients With Multiple Myeloma in the Second Line and Beyond
March 20th 2023This roundtable series reviews treatments in adult patients with multiple myeloma who have progressed on 1 or more lines of therapy, as discussed by key opinion leaders and participants at virtual live events.
Treating Patients With Breast Cancer After Progression on Endocrine Therapy
March 17th 2023This roundtable series explores therapies after progression on endocrine therapy in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer who have an ESR1 mutation,as discussed by key opinion leaders and participants at virtual live events.
Later-Line Combination Therapies Used as Treatment in Multiple Myeloma
March 13th 2023This roundtable series considers the use of combination treatments in patients with relapsed/refractory multiple myeloma who have received 2 or more lines of therapy, as discussed by key opinion leaders and participants at virtual live events.
How to Recognize, Diagnose, and Treat Patients With BPDCN
September 28th 2022This roundtable series discusses blastic plasmacytoid dendritic cell neoplasms in patients and the ways to identify and provide therapy for this rare disease, as discussed by key opinion leaders and participants at virtual live events.